|
1
|
Min A, Zhu C, Peng S, Rajthala S, Costea
DE and Sapkota D: MicroRNAs as important players and biomarkers in
oral carcinogenesis. BioMed Res Int. 2015:1869042015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bhattacharya A, Roy R, Snijders AM,
Hamilton G, Paquette J, Tokuyasu T, Bengtsson H, Jordan RC, Olshen
AB, Pinkel D, et al: Two distinct routes to oral cancer differing
in genome instability and risk for cervical node metastasis. Clin
Cancer Res. 17:7024–7034. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liang L, Zhang T, Kong Q, Liang J and Liao
G: A meta-analysis on selective versus comprehensive neck
dissection in oral squamous cell carcinoma patients with clinically
node-positive neck. Oral Oncol. 51:1076–1081. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar :
|
|
6
|
Kikkawa N, Hanazawa T, Fujimura L, Nohata
N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki
N: miR-489 is a tumour-suppressive miRNA target PTPN11 in
hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer.
103:877–884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nohata N, Hanazawa T, Kikkawa N, Sakurai
D, Fujimura L, Chiyomaru T, Kawakami K, Yoshino H, Enokida H,
Nakagawa M, et al: Tumour suppressive microRNA-874 regulates novel
cancer networks in maxillary sinus squamous cell carcinoma. Br J
Cancer. 105:833–841. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fukumoto I, Kinoshita T, Hanazawa T,
Kikkawa N, Chiyomaru T, Enokida H, Yamamoto N, Goto Y, Nishikawa R,
Nakagawa M, et al: Identification of tumour suppressive
microRNA-451a in hypopharyngeal squamous cell carcinoma based on
microRNA expression signature. Br J Cancer. 111:386–394. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fukumoto I, Hanazawa T, Kinoshita T,
Kikkawa N, Koshizuka K, Goto Y, Nishikawa R, Chiyomaru T, Enokida
H, Nakagawa M, et al: MicroRNA expression signature of oral
squamous cell carcinoma: Functional role of microRNA-26a/b in the
modulation of novel cancer pathways. Br J Cancer. 112:891–900.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nohata N, Hanazawa T, Kikkawa N, Mutallip
M, Sakurai D, Fujimura L, Kawakami K, Chiyomaru T, Yoshino H,
Enokida H, et al: Tumor suppressive microRNA-375 regulates oncogene
AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). J Hum
Genet. 56:595–601. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nohata N, Hanazawa T, Kinoshita T, Inamine
A, Kikkawa N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Okamoto
Y, et al: Tumour-suppressive microRNA-874 contributes to cell
proliferation through targeting of histone deacetylase 1 in head
and neck squamous cell carcinoma. Br J Cancer. 108:1648–1658. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fuse M, Kojima S, Enokida H, Chiyomaru T,
Yoshino H, Nohata N, Kinoshita T, Sakamoto S, Naya Y, Nakagawa M,
et al: Tumor suppressive microRNAs (miR-222 and miR-31) regulate
molecular pathways based on microRNA expression signature in
prostate cancer. J Hum Genet. 57:691–699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goto Y, Kojima S, Nishikawa R, Kurozumi A,
Kato M, Enokida H, Matsushita R, Yamazaki K, Ishida Y, Nakagawa M,
et al: MicroRNA expression signature of castration-resistant
prostate cancer: The microRNA-221/222 cluster functions as a tumour
suppressor and disease progression marker. Br J Cancer.
113:1055–1065. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa
M, et al: The microRNA expression signature of bladder cancer by
deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goto Y, Kojima S, Nishikawa R, Enokida H,
Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T and Seki
N: The microRNA-23b/27b/24-1 cluster is a disease progression
marker and tumor suppressor in prostate cancer. Oncotarget.
5:7748–7759. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chiyomaru T, Seki N, Inoguchi S, Ishihara
T, Mataki H, Matsushita R, Goto Y, Nishikawa R, Tatarano S, Itesako
T, et al: Dual regulation of receptor tyrosine kinase genes EGFR
and c-Met by the tumor-suppressive microRNA-23b/27b cluster in
bladder cancer. Int J Oncol. 46:487–496. 2015.
|
|
17
|
Ishihara T, Seki N, Inoguchi S, Yoshino H,
Tatarano S, Yamada Y, Itesako T, Goto Y, Nishikawa R, Nakagawa M,
et al: Expression of the tumor suppressive miRNA-23b/27b cluster is
a good prognostic marker in clear cell renal cell carcinoma. J
Urol. 192:1822–1830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kinoshita T, Nohata N, Hanazawa T, Kikkawa
N, Yamamoto N, Yoshino H, Itesako T, Enokida H, Nakagawa M, Okamoto
Y, et al: Tumour-suppressive microRNA-29s inhibit cancer cell
migration and invasion by targeting laminin-integrin signalling in
head and neck squamous cell carcinoma. Br J Cancer. 109:2636–2645.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kinoshita T, Hanazawa T, Nohata N, Kikkawa
N, Enokida H, Yoshino H, Yamasaki T, Hidaka H, Nakagawa M, Okamoto
Y, et al: Tumor suppressive microRNA-218 inhibits cancer cell
migration and invasion through targeting laminin-332 in head and
neck squamous cell carcinoma. Oncotarget. 3:1386–1400. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fukumoto I, Kikkawa N, Matsushita R, Kato
M, Kurozumi A, Nishikawa R, Goto Y, Koshizuka K, Hanazawa T,
Enokida H, et al: Tumor-suppressive microRNAs (miR-26a/b,
miR-29a/b/c and miR-218) concertedly suppressed
metastasis-promoting LOXL2 in head and neck squamous cell
carcinoma. J Hum Genet. 61:109–118. 2016. View Article : Google Scholar
|
|
22
|
Cano A, Santamaría PG and Moreno-Bueno G:
LOXL2 in epithelial cell plasticity and tumor progression. Future
Oncol. 8:1095–1108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peinado H, Moreno-Bueno G, Hardisson D,
Pérez-Gómez E, Santos V, Mendiola M, de Diego JI, Nistal M,
Quintanilla M, Portillo F, et al: Lysyl oxidase-like 2 as a new
poor prognosis marker of squamous cell carcinomas. Cancer Res.
68:4541–4550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Harisi R and Jeney A: Extracellular matrix
as target for antitumor therapy. Onco Targets Ther. 8:1387–1398.
2015.PubMed/NCBI
|
|
25
|
Huang TT, Ping YH, Wang AM, Ke CC, Fang
WL, Huang KH, Lee HC, Chi CW and Yeh TS: The reciprocal regulation
loop of Notch2 pathway and miR-23b in controlling gastric
carcinogenesis. Oncotarget. 6:18012–18026. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li W, Liu Z, Chen L, Zhou L and Yao Y:
MicroRNA-23b is an independent prognostic marker and suppresses
ovarian cancer progression by targeting runt-related transcription
factor-2. FEBS Lett. 588:1608–1615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JJ, Drakaki A, Iliopoulos D and Struhl
K: MiR-27b targets PPARγ to inhibit growth, tumor progression and
the inflammatory response in neuroblastoma cells. Oncogene.
31:3818–3825. 2012. View Article : Google Scholar
|
|
28
|
Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z,
Chen Z, Qiu F, Xu J and Huang J: miRNA-27b targets vascular
endothelial growth factor C to inhibit tumor progression and
angiogenesis in colorectal cancer. PLoS One. 8:e606872013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Majid S, Dar AA, Saini S, Arora S,
Shahryari V, Zaman MS, Chang I, Yamamura S, Tanaka Y, Deng G, et
al: miR-23b represses proto-oncogene Src kinase and functions as
methylation-silenced tumor suppressor with diagnostic and
prognostic significance in prostate cancer. Cancer Res.
72:6435–6446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ishteiwy RA, Ward TM, Dykxhoorn DM and
Burnstein KL: The microRNA -23b/-27b cluster suppresses the
metastatic phenotype of castration-resistant prostate cancer cells.
PLoS One. 7:e521062012. View Article : Google Scholar
|
|
31
|
Ell B, Qiu Q, Wei Y, Mercatali L, Ibrahim
T, Amadori D and Kang Y: The microRNA-23b/27b/24 cluster promotes
breast cancer lung metastasis by targeting metastasis-suppressive
gene prosaposin. J Biol Chem. 289:21888–21895. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Blumenschein GR Jr, Mills GB and
Gonzalez-Angulo AM: Targeting the hepatocyte growth factor-cMET
axis in cancer therapy. J Clin Oncol. 30:3287–3296. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Seiwert TY, Jagadeeswaran R, Faoro L,
Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen
EE, Lingen MW, et al: The MET receptor tyrosine kinase is a
potential novel therapeutic target for head and neck squamous cell
carcinoma. Cancer Res. 69:3021–3031. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sacco AG and Cohen EE: Current treatment
options for recurrent or metastatic head and neck squamous cell
carcinoma. J Clin Oncol. 33:3305–3313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bertotti A and Sassi F: Molecular
pathways: Sensitivity and resistance to anti-EGFR antibodies. Clin
Cancer Res. 21:3377–3383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y
and Qu X: Cetuximab-induced MET activation acts as a novel
resistance mechanism in colon cancer cells. Int J Mol Sci.
15:5838–5851. 2014. View Article : Google Scholar : PubMed/NCBI
|
